Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 4/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8271615 | 0.94 | GRM2 (0.51) | GRM2HTR2CHCRTR1HCRTR2 | |
| SCHEMBL12442446 | 0.93 | GRM2 (0.50) | GRM2HTR2CHCRTR1HCRTR2GRIN2B | |
| SCHEMBL2029729 | 0.90 | GRM2 (0.52) | GRM2HCRTR1HCRTR2ALDH1A1GRIN2B | |
| SCHEMBL8270181 | 0.86 | GRM2 (0.57) | GRM2HTR2CHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL2026779 | 0.86 | GRM2 (0.57) | GRM2HTR2CHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL12580820 | 0.85 | GRM2 (0.56) | GRM2HTR2CHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL2022261 | 0.84 | GRM2 (0.55) | GRM2HTR2CHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL2025995 | 0.84 | GRM2 (0.55) | GRM2HTR2CHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL2022164 | 0.84 | GRM2 (0.54) | GRM2HTR2CHCRTR1HCRTR2ALDH1A1 | |
| SCHEMBL2023199 | 0.84 | GRM2 (0.54) | GRM2HTR2CHCRTR1HCRTR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | GRM2 4/4885HTR2C 616/4885HCRTR1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.